studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 1121A
majority were male (HBV DC 82%, HBV HCC 86%, HCV DC
76%, HCV HCC 81%). The number of incident hospitalizations
for HCV DC and HCV HCC has increased over time (Figure).
In contrast, incident hospitalizations for HBV DC and HBV HCC
have remained stable (Figure). Over the study period, estimated
uptake of antiviral therapy has increased for HBV (2% to
5%), but remained low for HCV (1-2% per annum). Conclusion
The burden of HCV-related hospitalizations due to ESLD has
increased markedly. Planned linkage to individual-level data
on HBV and HCV antiviral therapy prescriptions should provide
further insights into the contrasting pattern in ESLD burden.
Population level monitoring of HCV ESLD burden will be particularly
crucial to evaluate the impact of interferon-free regimens.
Disclosures:
Senaka Peter - Employment: Merck
Allan J. Collins - Advisory Committees or Review Panels: KDIGO, Amgen, IKEA-J,
NKF KDPN, Hospira; Board Membership: Kidney Health Australia; Consulting:
Amgen, NxStage, Keryx, Hospira, Relypsa, Bayer, ZS Pharma; Employment:
Hennepin Healthcare System; Grant/Research Support: Amgen, Merck,
NxStage, ZS Pharma, Keryx, Peer Kidney Care Initiative; Speaking and Teaching:
Hospira, Amgen
Jean Marie Arduino - Employment: Merck & Co., Inc
The following authors have nothing to disclose: Craig Solid, Tanya Bovitz, Haifeng
Guo
1868
Trends in end-stage liver disease among people notified
with HBV or HCV in New South Wales, Australia: 2000-
2014
Reem K. Waziry 1 , Jason Grebely 1 , Janaki Amin 1 , Maryam Alavi 1 ,
Behzad Hajarizadeh 1 , Jacob George 2 , Gail Matthews 1 , Matthew
Law 1 , Gregory Dore 1 ; 1 The Kirby institute, University of New South
Wales, Sydney, NSW, Australia; 2 Storr Liver Unit, Westmead Millennium
Institute for Medical Research and Westmead Hospital,
University of Sydney, Westmead, NSW, Australia, Sydney, NSW,
Australia
Study aims To assess trends in hospitalizations for end-stage
liver disease (ESLD); (decompensated cirrhosis (DC) and hepatocellular
carcinoma (HCC)) among people notified with HBV
or HCV in New South Wales (NSW), Australia. Methods
HBV and HCV cases notified to the NSW Health Department
between 1993 and 2012 were linked to data on hospitalizations
(2000-2014). Time trends in hospitalizations (incident
and total) due to DC (including ascites, esophageal varices
with bleeding, hepatic failure, alcoholic hepatic failure, and
alcoholic liver cirrhosis) and HCC were evaluated [International
Classification of Diseases (ICD 10) coding]. Results
Between 1993 and 2012, a total of 151,307 individuals were
notified with HBV (n=54,399), HCV (n=93,099), or HBV/
HCV (n=3,809). From 2000 to 2014, there were 24,130
(HBV=2,346; HCV=20,713, HBV/HCV=1,071) and 7,044
(HBV=2,583; HCV=4,180, HBV/HCV =281) hospitalizations
for DC and HCC, respectively. Among all hospitalizations
for ESLD, the number of incident hospitalizations was
6,031 (HBV=907, HCV=4,848, HBV/HCV=276) for DC and
2,055 (HBV=732, HCV=1,244, HBV/HCV=79) for HCC.
Median age at admission with ESLD was 57 (IQR=12) and
58 (IQR=20) for HBV DC, 61 (IQR=16) for HBV HCC, and 51
(IQR=11) for HCV DC and 58 (IQR=13) for HCV HCC .The
Disclosures:
Jason Grebely - Advisory Committees or Review Panels: Merck, Gilead; Grant/
Research Support: Merck, Gilead, Abbvie, BMS
Jacob George - Advisory Committees or Review Panels: Roche, BMS, MSD,
Gilead, Janssen, Abbvie; Grant/Research Support: MSD
Gail Matthews - Advisory Committees or Review Panels: gilead; Consulting: Viiv;
Grant/Research Support: Gilead Sciences, janssen; Speaking and Teaching:
BMS, MSD
Matthew Law - Grant/Research Support: Boehringer Ingelhiem, Gilead Sciences,
Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag, ViiV HealthCare
Gregory Dore - Board Membership: Gilead, Merck, Abbvie, Bristol-Myers
Squibb; Grant/Research Support: Gilead, Merck, Abbvie, Bristol-Myers Squibb;
Speaking and Teaching: Gilead, Merck, Abbvie, Bristol-Myers Squibb
The following authors have nothing to disclose: Reem K. Waziry, Janaki Amin,
Maryam Alavi, Behzad Hajarizadeh
1869
The influence of Hepatitis C virus infection and its clearance
on the serum lipid profile and glucose level
Yinping Li, Xiaomei Wang, Hongqin Xu, Ruihong Wu, Xiumei Chi,
Xiuzhu Gao, Yu Pan, Junqi Niu; Hepatology, The First Hospital of
Jilin University, Changchun, China
Chronic hepatitis C (CHC) is associated with a disturbance of
lipid metabolism and glucose intolerance, and the clearance
of HCV may be followed by a decrease in serum total cholesterol
(TC), triglyceride (TG) and insulin resistance to adverse
levels. The present study was designed to determine the impact
of CHC and its treatment on circulating lipids and glucose
levels. A total of 748 patients with HCV infection were retrospectively
enrolled, Fasting serum total cholesterol (TC), triglyceride
(TG) and blood glucose (FBG) levels in these patients
were compared with 664 healthy individuals. Serum TC, TG
and systematic glucose metabolism were measured in 183
patients with chronic hepatitis C receiving interferon α-2b plus
ribavirin at baseline, at the end of treatment, and at week 24
post-treatment. We analysed systemic glucose metabolism in
terms of the following indices: fasting insulin (FINS), C-peptide
(FCP), homeostasis model assessment for insulin resistance
(HOMA-IR) and beta-cell function (HOMA-β) and the insulin